Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.56 |
| ▸ | CMA1 | P23946 | 2/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.40 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21510173 | 0.86 | AHR (0.53) | AHRCMA1EIF2AK2PDK2CRBN | |
| SCHEMBL2611053 | 0.86 | AHR (0.56) | AHRCMA1PDK2HPGDGFER | |
| SCHEMBL2611058 | 0.84 | CA9 (0.57) | CRBNHPGDGFERHSD17B10KMT2A | |
| SCHEMBL29754329 | 0.84 | CA9 (0.57) | CRBNHPGDGFERHSD17B10KMT2A | |
| SCHEMBL20889632 | 0.83 | AHR (0.50) | AHRCMA1EIF2AK2PDK2CRBN | |
| SCHEMBL13620314 | 0.83 | AHR (0.50) | AHRCMA1EIF2AK2PDK2CRBN | |
| SCHEMBL13772562 | 0.83 | AHR (0.50) | AHRCMA1EIF2AK2PDK2CRBN | |
| SCHEMBL4467581 | 0.83 | CRBN (0.57) | AHRCMA1EIF2AK2CRBNKIF11 | |
| SCHEMBL7478751 | 0.82 | AHR (0.56) | AHRCMA1EIF2AK2PDK2CRBN | |
| SCHEMBL15703052 | 0.81 | MAPT (0.53) | AHRCMA1CRBNHPGDGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076635-A2 | SUPPRESSORS OF SITE IQ ELECTRON LEAK AND USES THEREOF | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4186896-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2009143477-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1844050-B1 | PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2008008539-A2 | FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | AMGEN INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
| US-4791129-A | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4725616-A | ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| CN-86105309-A | Oxindole-3-carbonyl amines the compound that replaces as the 1-of anti-inflammatory and anodyne | — | 1987-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | AHR 1433/4885CMA1 3231/4885EIF2AK2 699/4885 |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | AHR 308/4885CMA1 234/4885EIF2AK2 1253/4885 |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | PRKDC, MAP3K20, MAP3K5 | AHR 4279/4885CMA1 2807/4885EIF2AK2 596/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | AHR 4129/4885CMA1 3953/4885EIF2AK2 1647/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | AHR 3847/4885CMA1 3987/4885EIF2AK2 716/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | AHR 590/4885CMA1 2455/4885EIF2AK2 2244/4885 |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | AHR 3120/4885CMA1 3176/4885EIF2AK2 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.